Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
37691
CAS Number:
866323-14-0
Bélinostat
Purity:
≥ 98 % (HPLC)
Synonym(s):
( E )- N -Hydroxy-3-[3-(N-phénylsulfamoyl)phényl]acrylamide
Documents
$251.68 /25 mg
Taille
Request Bulk Quote
Informations sur le produit

Belinostat is a potent histone deacetylase (HDAC) inhibitor, recognized for its significant role in cancer therapy, particularly in the treatment of peripheral T-cell lymphoma (PTCL). This compound functions by altering the expression of genes involved in cell cycle regulation and apoptosis, making it a valuable tool in oncology research and therapeutic applications. Belinostat's unique mechanism of action allows it to enhance the efficacy of other anticancer agents, providing a synergistic effect that can lead to improved patient outcomes.

In addition to its primary use in cancer treatment, Belinostat is being explored for its potential applications in various other therapeutic areas, including neurodegenerative diseases and inflammatory disorders. Its ability to modulate gene expression makes it a promising candidate for research into epigenetic therapies. Researchers and industry professionals can leverage Belinostat's properties to develop innovative treatment strategies and explore new avenues in drug development, making it an essential compound in the pharmaceutical landscape.

Numéro CAS 
866323-14-0
Formule moléculaire
C15H14N2O4S
Poids moléculaire 
318.35
Point de fusion 
160 °C (déc.)
Informations générales
Numéro CAS 
866323-14-0
Formule moléculaire
C15H14N2O4S
Poids moléculaire 
318.35
Point de fusion 
160 °C (déc.)
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Belinostat is widely utilized in research focused on:

  • Cancer Treatment: Primarily used in oncology, Belinostat is an FDA-approved drug for treating peripheral T-cell lymphoma, providing a targeted approach to combat this aggressive cancer type.
  • Histone Deacetylase Inhibition: As a histone deacetylase (HDAC) inhibitor, it plays a crucial role in epigenetic regulation, making it valuable for studies on gene expression and cellular differentiation.
  • Combination Therapies: Researchers are exploring its effectiveness in combination with other cancer therapies, enhancing treatment efficacy and potentially reducing resistance in cancer cells.
  • Preclinical Studies: Belinostat is frequently used in laboratory settings to investigate its effects on various cancer cell lines, aiding in the development of new therapeutic strategies.
  • Potential in Other Diseases: Beyond cancer, ongoing research is examining its role in treating other conditions, such as autoimmune diseases, showcasing its versatility in therapeutic applications.

Citations